MedTrace Logo

Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder

NCT00127270 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 395

Last updated 2008-01-24

No results posted yet for this study

Summary

This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.

Conditions

Interventions

DRUG

Darifenacin

Darifenacin tablets 7,5 mg once daily with the possibility to up-titrate to 15 mg once daily

DRUG

Darifenacin

Darifenacin tablets 7,5 mg or 15 mg once daily

BEHAVIORAL

Behavioral therapy

Behavioral Modification Programme for symptoms of overactive bladder

Sponsors & Collaborators

  • Procter and Gamble

    collaborator INDUSTRY

  • Novartis

    lead INDUSTRY

Principal Investigators

  • Novartis Pharmaceuticals Corp. · Novartis Pharmaceutical

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Completion
2006-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00127270 on ClinicalTrials.gov